|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||419.25 - 434.90|
|52-week range||419.25 - 604.50|
|Beta (3Y monthly)||N/A|
|PE ratio (TTM)||49.60|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Shares of Sun Pharmaceutical Industries rose over 2 per cent in early trade on the Bombay Stock Exchange after the drug maker clarified that it has not been involved in any insider trading norm violations relating to the Ranbaxy deal.
Reacting negatively to the whistleblower allegations, shares of Mumbai-headquartered company declined as much as 10.22 per cent in intra-day trade to Rs 441.95 apiece on the BSE, after opening lower at Rs 467.
Sun Pharmaceutical, its managing director Dilip Shanghvi and nine othes settled an insider trading probe on payment of Rs 18 lakh towards settlement charges.
India's largest drugmaker by market capitalisation made a provision of 12.14 billion rupee ($167 million) for estimated settlements with remaining plaintiffs in U.S. antitrust litigation related to its sleep disorder drug Modafinil, leaving it with a 2.19 billion rupee loss in the three months to Sept. 30, the company said on Tuesday.
Sun Pharmaceutical Industries Ltd. in a stock exchange filing reported a net profit of Rs 983 crore for the April-June quarter against a loss of Rs 425 crore in the same period last year. For the year-ago period, the company had
Geojit recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 597 in its research report dated June 19, 2018.
The company has received the EIR (establishment inspection report) from the USFDA for the inspection conducted at its Halol facility (Gujarat, India) during the period February 12-23, 2018.
Supply restrictions imposed on India's largest drugmaker Sun Pharmaceutical Industries by U.S. regulators have been lifted, the company said on Tuesday, removing a major drag on its share price. Sun will now be able to resume shipments of drugs made at its Halol factory in western India, which contributed as much as 15 percent to its U.S. revenue in 2015. The restrictions on some drugs made at the site had been imposed after an inspection revealed quality control failures.
Khambatta Securities is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 582 in its research report dated May 30, 2018.
According to a report on CNBC-TV18, the company has received a voluntary action initiated (VAI) status for its Halol plant from US FDA.
Makers of generic drugs have seen poor sales as uncertainty grows in the global market for copycat drugs due to rising competition and pricing scrutiny in the world's largest healthcare market. The warning compounds problems at Sun, which has been struggling to get clearance for its factories that are under U.S. supply bans due to quality control failures. It now plans to reduce its research spend on some generic drug projects that have become "unviable", Dilip Shanghvi, the company's founder and managing director, said on a conference call with analysts.
Mumbai, May 25 (IANS) Pharma major Sun Pharmaceutical Industries on Friday reported a rise of 6.96 per cent in its consolidated net profit for the quarter ended March 31, 2018. According to the company, its profit after tax for the quarter under review increased to Rs 1,308.96 crore from Rs 1,223.71 crore reported for the corresponding quarter of previous fiscal. Commenting on the financial performance, Dilip Shanghvi, Managing Director of the Company said: "Our Q4 performance is in-line with our guidance.
Mumbai, May 25 (IANS) Pharma major Sun Pharmaceutical Industries on Friday reported a rise of 6.96 per cent in its consolidated net profit for the quarter ended March 31, 2018. According to the company, its profit after tax for the quarter under review increased to Rs 1,308.96 crore from Rs 1,223.71 crore reported for the corresponding quarter of previous fiscal. However, in terms of financial year, the pharma major's consolidated net profit declined by 68.96 per cent to Rs 2,161.55 crore from Rs 6,964.37 crore reported for 2016-17.
In a regulatory filing, Sun Pharma and Churchill Pharmaceuticals, LLC said "one of Sun Pharma's wholly owned subsidiary companies has received approval from the US Food and Drug Administration (USFDA) for YONSA."
Sun Pharmaceutical Industries and Churchill Pharmaceuticals, LLC today announced that one of Sun Pharma’s wholly owned subsidiary companies has received approval from the U.S. Food and Drug Administration (FDA) for YONSA (abiraterone acetate), a novel formulation in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Sun Pharma, along with other Indian pharmaceutical companies, has been battling increased competition in the generics market and greater pricing scrutiny in the United States. The drugmaker has also struggled as some of its products were banned from sale in the United States because the factories that made them did not meet U.S. quality standards. It was also hit by adjustments for U.S. tax reforms in the third quarter.